LSE:AZN
LSE:AZNPharmaceuticals

AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer

AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting significant advancements in treatment for high-risk non-muscle-invasive bladder cancer. This development coincided with a 5.93% share price increase over the past month. The company's recent announcements, such as the Calquence approval in the EU and positive results from the DESTINY-Breast11 trial, have reinforced its commitment to innovative treatments. While market...